CAP-XX Limited announced that Portal Instruments has selected the CAP-XX GS230F supercap for its advanced needle-free drug delivery platform for self-administering biological medicines. Portal Instruments chose the CAP-XX prismatic supercapacitors, which are manufactured in CAP-XX's production facilities in Australia and Malaysia, due to their characteristic low Equivalent Series Resistance (ESR) which enables the high burst of energy needed to drive the fast, large volume needle-free jet injection, and for their thin form factor which fits easily inside the small drug delivery device. Portal Instruments' needle-free jet injection platform is intended to simplify the drug delivery experience, from self-injection for patients suffering from chronic disease, to healthcare workers delivering vaccines. The handheld connected device delivers injectable medications without a needle by pressurizing the drug itself, which passes through a 160 µm nozzle to create a very fine fluid jet, about the size of a hair, at a controlled speed. This jet pierces the skin, delivering the drug to the target tissue in a fraction of a second, up to 30x faster than a conventional autoinjector and with less pain. Portal's platform can deliver injection volumes up to 2 mL, irrespective of drug concentration and viscosity. Portal Instruments uses multiple ultra-power-dense CAP-XX GS230F supercapacitors to deliver hundreds of watts of output power to drive the high-speed, concentrated injection in its compact handheld device. CAP-XX's industry-leading power density enables the device's small, easy-to-use form factor and allows the device to operate from a compact, industry-standard rechargeable battery which recharges the supercapacitors before every injection. The CAP-XX GS230F supercapacitor features: 1200 mF; 5 V; 39 x 17 x 3.9 mm; Very very low ESR of 25 mO (milliohm) which is critical in this fast drug delivery application;· Very low leakage current of 2.5 µA (micro-Amps).